Advisers & FriendsRobert H. Weiss, M.D.
|
Clinical/Research InterestsRobert H. Weiss' clinical interests include the diagnosis and treatment of all renal diseases and electrolyte problems. His research interests concern the cyclins and cyclin inhibitors, cancer growth control (kidney and breast cancer), metabolomics and proteomics, and polycystic kidney disease. |
Title: |
Professor Chief of Nephrology, Sacramento VA Medical Center |
Specialty: |
Nephrology |
Education: |
UC Irvine College of Medicine Irvine, California M.D. 1984 |
|
UCLA Los Angeles, California M.S. 1980 UC Santa Cruz Santa Cruz, California B.A. 1976 |
|
Internships: |
California-Pacific Medical Center San Francisco, California 1984-85 Internal Medicine |
Residency: |
California-Pacific Medical Center San Francisco, California 1985-87 Internal Medicine |
Fellowships: |
University of California, San Francisco San Francisco, California 1991 Nephrology |
Board Certifications: |
American Board of Internal Medicine, Nephrology, 1996 American Board of Internal Medicine, 1987 |
Professional Memberships: |
American Association for the Advancement of Science American College of Physicians American Society of Nephrology |
Select Recent Publications: |
Kim, K.M., Aronov, P.A., Zakharkin, S.O., Anderson, D., Perroud, B., Weiss, R.H., Urine metabolomic analysis for kidney cancer detection and biomarker discovery, Molecular and Cellular Proteomics, Mar;8(3):558-70, 2009 Perroud, B., Ishimaru, T., Borowsky, A.D., Weiss, R.H. Grade-dependent proteomic characterization of kidney cancer, Molecular and Cellular Proteomics, May;8(5):971-85, 2009 Liu , J.-Y. Park, S.-H., Morisseau , C., Hwang , S. H., Hammock, B., Weiss, R.H., Sorafenib Has sEH Inhibitory Activity Which Contributes to Its Effect Profile in vivo, Molecular Cancer Therapeutics, 2009 Aug;8(8):2193-203. Son, A., Dhirapong, A., Dosev, D., Kennedy, I., Weiss, R.H., Hristova, K. Quantitative detection of PKD genetic mutations using magnetic/luminescent nanoparticles, Analytical and Bioanalytical Chemistry, 390(7):1829-35, 2008 Park, S.H., Park, J.Y., Weiss, R.H. Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA-damaging chemotherapy associated with enhancement of phospho-p53, Journal of Urology 180(1):352-60, 2008 Park, S.H., Wang, X., Liu, R., Lam, K.S., Weiss, R.H. High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers, Cancer Biology & Therapy, Dec 26;7(12), 2015-22, 2008 Park, J.Y., Park, S.H., Weiss, R.H., Disparate effects of roscovitine on renal tubular epithelial cell apoptosis and senescence: Implications for ADPKD, American Journal of Nephrology, Dec 10;29(6):509-515, 2008 Weiss, R.H., Borowsky, A.D., Seligson, D. Lin, P.-Y., Dillard-Telm, L., Belldegrun, A. S., Figlin, R.A., Pantuck, A.D. p21 is a prognostic marker in renal cell carcinoma: Implications for novel therapeutic approaches, Journal of Urology, Jan;177(1):63-69, 2007 Kind, T., Tolstikov, V., Fiehn, O., Weiss, R.H. A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal Biochem. 363(2):185-95, 2007 Lin, P.Y., Fosmire, S.P., Baksh, S., Modiano, J.F., Weiss, R.H. Attenuation of PTEN increases p21 stability and cytosolic localization: a potential mechanism of apoptosis resistance, Molecular Cancer, 6:16, 2007 |
